[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"retinitis-pigmentosa-rp\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:retinitis-pigmentosa-rp":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,15,0,[8,76,102,143,176,198,227,263,287,309,352,376,396,420,443],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":37,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":69,"completionDateStruct":70,"leadSponsor":72,"locationsCount":75},"100619218","brain-stimulation-effects-on-orientation-and-mobility-skills-in-adults-with-vision-impairment-100619218",false,"NCT07341763","Brain Stimulation Effects on Orientation and Mobility Skills in Adults With Vision Impairment","A Randomized, Double-Blind, Placebo-Controlled Pilot Study to Evaluate Non-invasive Brain Stimulation Effects on Orientation and Mobility Performance in Adults With Visual Impairments","Inclusion Criteria:\n\n* Are healthy, capacitated adults with binocular constricted visual field loss (due to either retinitis pigmentosa (RP), rod-cone dystrophy, or advanced glaucoma) resulting in functional vision losses. These individuals with visual impairments can be those who have been previously trained by an Orientation and Mobility (O\\&M) specialist to independently travel with the long white cane daily (since the length of the white cane and tip at the base are based on personal preference, they should be willing to use their own white cane for the study), and those who do not necessarily use a cane for travelling.\n* Have binocular visual acuity or best corrected binocular visual acuity no worse than 6\u002F12 or 20\u002F40 or +0.30 logMAR (inclusive) with no eccentric viewing and binocular visual fields no better than 50 degrees in total in each eye as given by the Humphrey Field analyzer and no better than 50 degrees binocularly as given by arc perimeter test. The Humphrey Field Analyzer measures static visual field test, whereas the Arc perimeter test measures kinetic visual field test. Measuring kinetic and static visual field would promote a greater understanding of the individual's daily performance.\n* Are over the age of 18 (inclusive) and has full legal capacity to provide informed consent.\n* Have read and fully comprehends the information in the consent letter.\n* Are willing and capable of adhering to instructions and maintaining the outlined appointment schedule.\n\nExclusion Criteria:\n\n* Are involved in other recent eye-related studies, either clinical or research-related. To be eligible they would have to wait at least one week for studies not involving brain stimulation, and four weeks for studies in which they receive brain stimulation before they could participate in this study.\n* Have been diagnosed with dementia or self-reported dementia with no formal diagnosis.\n* Have been diagnosed with a cognitive impairment or self-reported cognitive impairment with no formal diagnosis.\n* Have been diagnosed with physical or motor impairments resulting in walking and\u002For balancing issues or self-reported physical or motor impairments resulting in walking and\u002For balancing issues with no formal diagnosis.\n* Have been diagnosed with vestibular disorders or dysfunctions which affects one's balance and\u002For mobility or self-reported vestibular disorders or dysfunctions which affects one's balance and\u002For mobility with no formal diagnosis.\n* Are unable to follow the researcher's instructions.\n* Are anticipating treatment (including ocular surgery) for any eye disease within the duration of the study.\n* Have any ocular pathology in addition to retinitis pigmentosa (RP), rod-cone dystrophy, or advanced glaucoma, which can diminish their visual acuity and\u002For their visual field, however wearing glasses or contact lenses, as well as mild cataract of grade 2 or below is acceptable.\n* Have severe hearing impairment.\n* Are pregnant or trying to get pregnant.\n* Fit any of the typical contraindicators for brain stimulation. See contraindicator section below.\n\nFor all participants the contraindications for brain stimulation are:\n\n* Diagnosed with epilepsy or have previously experienced an epileptic seizure.\n* Implanted medication pump or implanted electronic device, including defibrillator or pacemaker.\n* Any metal implants in the head (excluding tooth fillings).\n* Active electric implants anywhere in the body (especially the head region).\n* On psychoactive medication for any psychiatric or neurological conditions including but not limited to depression and schizophrenia.\n* Areas of sensitive skin located on the face or head, or a skin condition on the face, or regularly use medication to alleviate skin irritation on the face.\n* Recurring headaches.\n* Previous head injury or skull fracture or head\u002Fbrain surgery.\n* Heart disease, neurological condition, or a history of cardiac or neurological surgery.\n* Current or historical cancerous or noncancerous brain tumor, or other abnormalities in brain structure.","ALL","18 Years",{"count":19,"type":20},20,"ESTIMATED","INTERVENTIONAL",[23],"NA","This pilot clinical trial evaluates whether non-invasive brain stimulation improves the orientation and mobility (O\\&M) skills of individuals with constricted visual fields in both eyes. The study is composed of three visits. The first visit is meant to confirm eligibility by performing a few clinical tests. Eligible participants will then complete two additional visits, one in which the participants receive active stimulation, and one in which the participants receive placebo (sham) stimulation. Stimulation will be administered in a randomized, double-blind order. To evaluate improvement, various measures of O\\&M performance will be assessed on a standardized obstacle course featuring static natural and artificial obstacles at defined intervals after the intervention. We hypothesize that the application of hf-tRNS to V1 will improve the orientation and mobility skills of individuals with constricted visual fields immediately following stimulation as a results of enhanced periphery through modulation of the mechanisms responsible for crowding, thereby reducing crowding effects and improving contrast for individuals with rod-cone dystrophy and RP (genetic conditions), whereas for individuals with glaucoma (a neurogenerative condition), any improvement noted would be attributed to be enhanced processing of visual signal in the affected periphery. The results will inform the design of a future, larger-scale study.",[26,27,28,29,30,31,32,33,34,35,36],"Retinitis Pigmentosa (RP)","Rod Cone Dystrophy","Visually Impaired Persons","Peripheral Visual Field Defect of Both Eyes","Low Vision, Both Eyes","Vision Loss Partial","Orientation","Mobility Difficulty","Mobility Limitation","Mobility and Independence","Glaucoma",[26,38,39,28,29,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63],"Rod Cone dystrophy","Advanced Glaucoma","Low Vision, Both eyes","Brain stimulation","tES","tRNS","hf-tRNS","transcranial electrical stimulation","transcranial random noise stimulation","high-frequency transcranial random noise stimulation","Long white cane","white cane","mobility cane","walking","orientation and mobility","orientation","mobility","low vision","vision loss partial","occipital pole","primary visual cortex","V1","neuroplasticity","mobility difficulty","mobility limitation","mobility and independence","RECRUITING","2026-06-30",{"date":67,"type":68},"2026-07-01","ACTUAL",{"date":67,"type":20},{"date":71,"type":20},"2027-08-31",{"name":73,"class":74},"University of Waterloo","OTHER",1,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":21,"phases":85,"briefSummary":87,"conditions":88,"keywords":90,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":4},"100615278","phase-3-24-month-trial-of-npi-001-for-the-preservation-of-photoreceptors-in-retinitis-pigmentosa-associated-with-usher-syndrome-100615278","NCT07290530","24-Month Trial of NPI-001 for the Preservation of Photoreceptors in Retinitis Pigmentosa Associated With Usher Syndrome","A 24-Month, Randomized, Double-Masked, Placebo-Controlled Trial of NPI-001 for the Preservation of Photoreceptors in Retinitis Pigmentosa Associated With Usher Syndrome","Inclusion Criteria:\n\n1. Able to comprehend and willing to sign an informed consent form (ICF) and to adhere to the study protocol.\n2. Diagnosed with Usher syndrome.\n3. EZ zone width ≥ 500 microns, which includes the fovea in each eye at Visit 1 (Screening).\n4. All edges of the EZ area in both eyes can be visualized at Visit 1 (Screening).\n5. Have at least 20 detectable points on the MAIA grid in at least one eye at the Screening and Baseline visits (same eye for both visits).\n\n5\\. On stable dose of medications associated with other conditions for at least one month.\n\n6\\. Both female participants of childbearing potential and male participants able to father children must have (or have a partner who has) had a bilateral oophorectomy, hysterectomy or bilateral salpingectomy; must abstain from intercourse; or must agree to practice 2 acceptable methods of contraception throughout the course of the study and 4 weeks after the last visit. Acceptable methods of contraception include hormonal contraception (i.e., birth control pills, injected hormones, dermal patch or vaginal ring), intrauterine device, barrier methods (diaphragm, condom) with spermicide, tubal ligation, and vasectomy.\n\nExclusion Criteria:\n\n1. Concurrent retinal pathologies that result in vision loss or inability to fixate, including but not limited to, choroideremia, retinal vein occlusion, and neovascular age-related macular degeneration.\n2. Intraocular surgery within the last two months or capsulotomy within the last month.\n3. Current or history of uveitis, Coat's disease, diabetic retinopathy, glaucoma, herpes simplex of the eye, or currently has a cataract that prevents visualization of the posterior pole.\n4. Likely to require cataract surgery within the next 12 months.\n5. Unstable fixation during microperimetry in either eye at either Screening or Baseline visits.\n6. Use of any other investigational new drug, or participation in another clinical trial within 12 weeks before the start of study treatment.\n7. Use of N-acetylcysteine containing products in the previous 30 days prior to the baseline visit or unwilling to refrain from such supplements for the duration of the study.\n8. Chronic liver or kidney disease, cystic fibrosis, severe asthma, or chronic obstructive pulmonary disease (COPD), history of thrombocytopenia not due to a reversible cause, or other blood dyscrasia.\n9. Suspected liver dysfunction determined by having alanine aminotransferase (ALT), aspartate aminotransferase (AST), or bilirubin values \\> 1.5 X the upper limit of normal (ULN) at screening.\n10. Platelet or hemoglobin values \\\u003C 100 at screening.\n11. History of known sensitivity to N-acetylcysteine or similar thiol compounds or any ingredients of NPI-001.\n12. History of hypersensitivity to any medication or food resulting in systemic symptoms.\n13. History of cancer (other than non-melanoma skin cancer) diagnosed or requiring treatment within the past 2 years.\n14. Pregnant women or women planning to become pregnant in the next 25 months or men with partners planning to become pregnant in the next 25 months.\n15. Lactating women who are breast-feeding.\n16. Potential participant lives in the same household as a current participant in this study.\n17. Subjects who are willing or unable to refrain from donation of blood from 30 days prior to Screening, plasma from 2 weeks prior to Screening, or platelets from 6 weeks prior to Screening until 56 days following the last study drug dose administered.\n18. Inability to provide blood samples, including difficulty with venous access.\n19. Any reason, in the opinion of the Principal Investigator, the participant should not participate.",{"count":84,"type":20},80,[86],"PHASE3","The goal of this clinical trial is to learn if NPI-001 works to prevent progression of retinitis pigmentosa in adults diagnosed with Usher syndrome. It will also provide information about the safety of NPI-001. The main questions it aims to answer are:\n\nDoes NPI-001 slow down the loss of photoreceptors? What medical problems do participants have when taking NPI-001? Researchers will compare NPI-001 to a placebo (a look-alike substance that contains no drug) to see if NPI-001 works to preserve vision.\n\nParticipants will:\n\nTake NPI-001 or a placebo twice a day, every day for 24 months Visit the clinic 9 times for checkups and tests",[26,89],"Usher Syndrome",[91],"N-acetylcysteine amide","NOT_YET_RECRUITING","2026-06-28",{"date":67,"type":68},{"date":96,"type":20},"2026-12",{"date":98,"type":20},"2029-07",{"name":100,"class":101},"Nacuity Pharmaceuticals, Inc.","INDUSTRY",{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":108,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":16,"minAge":110,"maxAge":4,"enrollmentInfo":111,"targetDuration":4,"studyType":21,"phases":113,"briefSummary":115,"conditions":116,"keywords":123,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":142},"100564284","phase-2-study-to-evaluate-ultevursen-in-subjects-with-retinitis-pigmentosa-rp-due-to-mutations-in-exon-13-of-the-ush2a-gene-100564284","NCT06627179","Study to Evaluate Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene","A Two-Year Double-masked, Randomized, Sham-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Ultevursen in Subjects With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene","LUNA","Inclusion Criteria:\n\n1. An adult (≥18 years) willing and able to provide informed consent for participation prior to performing any study related procedures\n2. OR A minor (8 to \\\u003C18 years) able to provide age-appropriate assent for study participation with a parent or legal guardian willing and able to provide written permission for the subject's participation prior to performing any study related procedures. An adult willing to comply with the protocol, follow study instructions, attend study visits as required and willing and able to complete all study assessments, in the opinion of the Investigator.\n\n   OR A minor able to complete all study assessments and comply with the protocol and has a parent or caregiver willing and able to follow study instructions and attend study visits with the subject as required, in the opinion of the Investigator.\n3. Both eyes exhibit clinical presentation consistent with RP involving Usher syndrome type 2 or NSRP based on ophthalmic, audiologic, or vestibular examinations. At screening, the Investigator will make the clinical diagnosis of \"Usher syndrome type 2a,\" defined as RP with congenital hearing loss, or \"non-syndromic RP,\" defined as RP without congenital hearing loss.\n4. A molecular diagnosis of biallelic disease causing variants (pathogenic or likely pathogenic) in the USH2A gene where at least one of the variants is located on exon 13. A historic genotyping report from a certified laboratory is acceptable with Sponsor approval.\n5. Clearly visible and measurable SD-OCT horizontal EZ width of ≥2.2 mm in both eyes based on the assessment of the CRC.\n6. BCVA ≥55 letters based on ETDRS (equivalent to 20\u002F80 based on Snellen notation, or logarithm of the minimum angle of resolution \\[logMAR\\] +0.6) in both eyes.\n7. Impairment of VF as assessed by SP with a mean sensitivity greater than 4 decibels (dB) and less than 25 dB measured by a V target size in the TE at screening.\n8. Mean sensitivity greater than 2 dB as determined by MP in the TE at screening.\n9. Symmetry of baseline disease in both eyes, defined as the mean BCVA (based on ETDRS) of one eye within ≤10 letters of the mean BCVA of the other eye at screening.\n\nExclusion Criteria:\n\n1. Presence of additional non-exon 13 USH2A pathogenic or likely pathogenic variant on the USH2A allele carrying the exon 13 mutation in subjects who have one exon 13 disease causing variant and one non-exon 13 disease causing variant.\n2. Presence of additional non-exon 13 USH2A pathogenic mutation(s) on both USH2A alleles in subjects who have biallelic exon 13 mutations.\n3. Presence of pathogenic or likely pathogenic variants in genes (other than the USH2A gene) which are known to be associated with other inherited retinal degenerative diseases or syndromes. Specifically, the presence of homozygous or compound heterozygous known disease-causing mutations in other genes involved in recessive retinal dystrophies, or the confirmed presence of a known single disease-causing variant in genes involved in dominant, X-linked, or mitochondrial retinal dystrophy genes is exclusionary.\n4. At screening, the EZ horizontal or vertical width are outside the field of the SD-OCT scan based on the assessment of the CRC.\n5. Presence of any significant ocular or non-ocular disease\u002Fdisorder (including medication and laboratory test abnormalities) which, in the opinion of the Investigator may either put the subject at risk because of participation in the study, may impact the subject's ability to participate in the study, or may interfere with assessment of efficacy and safety in the study.\n6. Presence of unstable concurrent cystoid macular edema (CME), or subject started on (or changed dose of) any medication for CME in the 3 months prior to enrollment. CME is allowed if stable for 3 months (with or without treatment). However, stable CME that disrupts the EZ width measurement, as determined by CRC, is an exclusion.\n7. Any intraocular surgery within 3 months of study entry or any planned intraocular or peri-ocular surgery during the study. Subjects may be eligible after 3 months post-surgery as long as they have fully recovered, in the opinion of the Investigator.\n8. Receipt of any IVT injection prior to study entry.","8 Years",{"count":112,"type":20},81,[114],"PHASE2","The purpose of this Phase 2b study is to evaluate the safety and tolerability of ultevursen administered via intravitreal injection (IVT) in subjects with Retinitis Pigmentosa (RP) due to mutations in exon 13 of the USH2A gene. This is a multicenter Double-masked, Randomized, Sham-controlled study which will enroll 81 subjects.",[26,117,118,119,120,121,122],"Usher Syndrome Type 2","Deaf Blind","Retinal Disease","Eye Diseases, Hereditary","Eye Disorders Congenital","Vision Disorders",[124,117,118,125,126,127,128,129,130,108,131,132],"Retinitis Pigmentosa","USH2A","RP","Exon 13","RNA therapies","antisense oligonucleotide","exon skipping","IVT","NSRP","2026-06-16",{"date":135,"type":68},"2026-06-18",{"date":137,"type":68},"2024-12-11",{"date":139,"type":20},"2027-12",{"name":141,"class":101},"Laboratoires Thea",28,{"id":144,"slug":145,"hasResults":11,"nctId":146,"briefTitle":147,"officialTitle":148,"acronym":149,"eligibilityCriteria":150,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":151,"targetDuration":4,"studyType":153,"phases":4,"briefSummary":154,"conditions":155,"keywords":157,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":75},"100635150","observational-study-to-investigate-the-short-term-effects-of-transcorneal-electrical-stimulation-on-visual-performance-100635150","NCT07548944","Observational Study to Investigate the Short-term Effects of Transcorneal Electrical Stimulation on Visual Performance","Observational Study to Investigate the Short-term Effects of Transcorneal Electrical Stimulation (TES) on Visual Performance in Patients With Retinitis Pigmentosa and Similar Retinal Diseases","TES-STEP","Inclusion Criteria:\n\n* Adult patients (≥ 18 years) with clinically diagnosed retinitis pigmentosa (RP) or other similar degenerative retinal disease\n* Current treatment with TES using the OkuStim® System within the intended purpose\n* Subjective perception of short-term effects after TES treatment\n* Ability and willingness to give informed consent\n\nExclusion Criteria:\n\n* Cognitive, psychological, or linguistic limitations that prevent informed consent or proper study participation\n* Presence of other eye diseases (e.g., cataract, glaucoma, macular degeneration) that, in the opinion of the investigator, compromise or confound study assessments\n* Simultaneous participation in other clinical studies that could influence the results of the study\n* Severe comorbidities that could compromise patient safety or study conduct",{"count":152,"type":20},30,"OBSERVATIONAL","Retinitis pigmentosa and similar degenerative diseases of the retina lead to progressive loss of vision. TES therapy with the CE-marked OkuStim® System is a treatment approved in the EU for slowing the progression of the disease. Patients increasingly report short-term subjective improvements in vision, which have not yet been systematically investigated. This exploratory study is conducted to determine whether these subjective short-term effects can be measured, and therefore also be quantified, by objective tests.",[26,89,156],"Cone Rod Dystrophy",[158,159,160,161,162,163,164,165,166],"Transcorneal Electrical Stimulation","TES","OkuStim","Okuvision","Retinitis pigmentosa","Eye Diseases","Retinal Dystrophies","Retinal Degeneration","Retinal Diseases","2026-04-30",{"date":169,"type":68},"2026-05-01",{"date":171,"type":68},"2026-04-20",{"date":173,"type":20},"2027-03",{"name":175,"class":101},"Okuvision GmbH",{"id":177,"slug":178,"hasResults":11,"nctId":179,"briefTitle":180,"officialTitle":181,"acronym":4,"eligibilityCriteria":182,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":183,"targetDuration":4,"studyType":21,"phases":185,"briefSummary":186,"conditions":187,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":189,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":195,"locationsCount":197},"100602665","impact-of-capsular-tension-ring-on-intraocular-lens-position-in-retinitis-pigmentosa-cataract-patients-100602665","NCT07126470","Impact of Capsular Tension Ring on Intraocular Lens Position in Retinitis Pigmentosa Cataract Patients","Effect of Capsular Tension Ring Implantation on Postoperative IOL Position in Retinitis Pigmentosa Patients With Cataract: a Multi-center, Randomized, Self-controlled Study","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Clinical diagnosis of retinitis pigmentosa (RP).\n* Bilateral cataract meeting the indications for IOL implantation.\n* Willingness to participate in the study and provision of signed informed consent.\n\nExclusion Criteria:\n\n* History of intraocular surgery.\n* Severe zonular weakness (e.g., zonular dialysis \\>90°, lens subluxation\u002Fdislocation)\n* Other ocular comorbidity: such as pseudoexfoliation syndrome, ocular trauma, corneal dystrophies, uveitis, etc.\n* Severe systemic diseases: such as severe hypertension, diabetes, heart disease, Alzheimer's, Parkinson, etc.",{"count":184,"type":20},88,[23],"This is a self-controlled randomized clinical trial to investigate the effect of capsular tension ring (CTR) implantation on intraocular lens (IOL) position in cataract patients with retinitis pigmentosa(RP). Each patient will receive CTR implantation in one eye, with the fellow eye serving as control. Postoperative outcomes, including visual acuity, IOL position, and postoperative complications will be compared between eyes.",[188,26],"Cataract",{"date":190,"type":68},"2026-04-23",{"date":192,"type":68},"2025-08-25",{"date":194,"type":20},"2027-08",{"name":196,"class":74},"Zhongshan Ophthalmic Center, Sun Yat-sen University",3,{"id":199,"slug":200,"hasResults":11,"nctId":201,"briefTitle":202,"officialTitle":203,"acronym":204,"eligibilityCriteria":205,"healthyVolunteers":11,"sex":16,"minAge":206,"maxAge":207,"enrollmentInfo":208,"targetDuration":4,"studyType":21,"phases":210,"briefSummary":212,"conditions":213,"keywords":214,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":218,"lastUpdatePostDateStruct":219,"startDateStruct":221,"completionDateStruct":223,"leadSponsor":225,"locationsCount":4},"100614658","phase-1-prospective-randomized-sham-controlled-dose-finding-iii-trial-of-safety-and-efficacy-of-modified-optogenetic-gene-therapy-zm-02-injection-100614658","NCT07282457","Prospective, Randomized, Sham-controlled, Dose-finding I\u002FII Trial of Safety and Efficacy of Modified Optogenetic Gene Therapy (ZM-02 Injection)","A Prospective, Randomized, Sham-controlled, Dose-finding Phase 1\u002F2 Two-part Trial to Evaluate the Safety, Tolerability, and Efficacy of ZM-02 Injection in Patients With Advanced Retinitis Pigmentosa","PRISM","Inclusion Criteria\n\n1. Male or female participants aged 6 to 60 years.\n2. Clinical diagnosis of advanced retinitis pigmentosa (RP).\n3. Best corrected visual acuity at or below the protocol-defined threshold in the study eye.\n4. Presence of sufficient retinal structure in the study eye as determined by screening assessments.\n5. Ability to understand and sign informed consent (and assent, when applicable).\n\nExclusion Criteria\n\n1. Presence of other ocular conditions that could interfere with study assessments.\n2. History of significant ocular surgery in the study eye within a protocol-defined period.\n3. Active ocular infection or inflammation.\n4. Clinically significant systemic disease that could increase study risk or interfere with assessments.\n5. Positive screening for clinically significant infectious diseases, as defined in the protocol.\n6. Pregnant or breastfeeding individuals.\n7. Any condition that, in the investigator's judgment, would make the participant unsuitable for study participation.","6 Years","60 Years",{"count":209,"type":20},21,[211,114],"PHASE1","This is a Phase 1\u002F2, multi-center, randomized, sham-controlled, dose-escalation study evaluating ZM-02 in patients with advanced retinitis pigmentosa (RP).",[26],[215,216,126,217],"gene therapy","AAV","optogenetics","2026-04-09",{"date":220,"type":68},"2026-04-13",{"date":222,"type":20},"2026-06-25",{"date":224,"type":20},"2031-12-25",{"name":226,"class":101},"Zhongmou Therapeutics",{"id":228,"slug":229,"hasResults":11,"nctId":230,"briefTitle":231,"officialTitle":232,"acronym":233,"eligibilityCriteria":234,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":235,"targetDuration":4,"studyType":21,"phases":237,"briefSummary":238,"conditions":239,"keywords":246,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":254,"lastUpdatePostDateStruct":255,"startDateStruct":256,"completionDateStruct":258,"leadSponsor":260,"locationsCount":262},"100576757","phase-1-a-study-to-investigate-the-safety-of-opct-001-in-adults-who-have-primary-photoreceptor-disease-clarico-100576757","NCT06789445","A Study to Investigate the Safety of OpCT-001 in Adults Who Have Primary Photoreceptor Disease (CLARICO)","A Phase 1\u002F2a Study of Subretinal Administration of OpCT-001 Photoreceptor Precursor Cells Derived From iPSCs in Patients With Primary Photoreceptor Disease","CLARICO","Key Inclusion Criteria:\n\n* Confirmed genetic diagnosis of primary photoreceptor (PR) disease\n* Best corrected visual acuity (BCVA) in the study eye at Screening for Phase 1: Logmarithm of the minimum angle of resolution (LogMAR) 3.9 to LogMAR 1.3. BCVA at Screening for Phase 2: ETDRS letter score between 20 to 60, inclusive.\n* Retinal structure examination in the study eye demonstrating regions suitable for cell administration.\n\nKey Exclusion Criteria:\n\n* Clinically relevant, active ocular inflammation or infection\n* Glaucoma or other significant optic neuropathy\n* Diabetic macular edema or diabetic retinopathy\n* Clinically significant cystoid macular edema\n* In phakic participants: Spherical equivalent refractive error of greater than 8.00 diopters myopia\n* Ocular surgery ≤3 months before Screening\n* Monocular vision (ie, no light perception in the fellow eye)\n* Currently active malignancy, or history of malignancy within 5 years before OpCT-001 administration. Exception: Basal cell carcinoma that has been definitively treated.\n* Any current and active infection (bacterial\u002Fviral\u002Ffungal) that could put the participant at risk from immunosuppression\n* History of any cell therapy, gene therapy, or retinal implant at any time\n* Previously received a bone marrow or solid organ transplant",{"count":236,"type":20},54,[211,114],"Study OpCT-001-101 is a Phase 1\u002F2a first-in-human, multisite, 2-part interventional study to evaluate the safety, tolerability, and the effect on clinical outcomes of OpCT-001 in approximately 54 adults with primary photoreceptor (PR) disease. Phase 1 focuses on safety and features a dose-escalation design. Phase 2 is designed to gather additional safety data and assess the effect of OpCT-001 on measures of visual function, functional vision, and anatomic measures of engraftment in different clinical subgroups.",[240,26,89,241,242,243,165,244,245],"Primary Photoreceptor Disease","Inherited Retinal Disease (IRD)","Rod-Cone Dystrophy","Rod-Cone Disease","Cone-Rod Disease (C-RD)","Cone-Rod Dystrophy",[233,247,248,249,89,124,250,251,252,253],"Photoreceptor cells","Cell Therapy","Cellular Therapy","Inherited retinal disease (IRD)","Primary Photoreceptor disease (PPD)","Rod-Con Disease (R-CD)","Cone-Rose disease (C-RD)","2026-04-07",{"date":220,"type":68},{"date":257,"type":68},"2025-03-10",{"date":259,"type":20},"2030-10",{"name":261,"class":101},"BlueRock Therapeutics",4,{"id":264,"slug":265,"hasResults":11,"nctId":266,"briefTitle":267,"officialTitle":268,"acronym":269,"eligibilityCriteria":270,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":271,"targetDuration":4,"studyType":21,"phases":273,"briefSummary":274,"conditions":275,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":278,"lastUpdatePostDateStruct":279,"startDateStruct":281,"completionDateStruct":283,"leadSponsor":285,"locationsCount":75},"100613437","restoration-of-central-vision-with-prima-in-patients-with-photoreceptor-degeneration-100613437","NCT07266584","Restoration of Central Vision With PRIMA in Patients With Photoreceptor Degeneration","Restoration of Central Vision With the PRIMA Products in Patients With Photoreceptor Degeneration","PRIMAlia","Inclusion Criteria:\n\n1. Is 18 years or older at the date of inclusion;\n2. Has a confirmed diagnosis of inherited retinal degeneration with the macula affected in both eyes;\n3. The study eye has best corrected visual acuity of logMAR 1.2 (20\u002F320) or worse as measured by ETDRS test;\n4. Has an atrophic patch in the study eye including the fovea of at least the implant size (\\>4.5 mm2 and \\>2.4 mm in minimum diameter);\n5. Understands the constraints of the study and accepts to present for all scheduled follow-up visits;\n6. Signed the informed consent.\n\nExclusion Criteria:\n\n1. 1\\. Has cataract in the study eye (with LOCS III scale NO, NC, C or P\\>1); (these patients will need to have cataract surgery performed prior to completion of baseline testing; all other patients will get IOL replacement during the PRIMA Stim implantation);\n2. Underwent intraocular lens implantation in the study eye within the last month prior to enrolment (this corresponds to 4 weeks or 28 days) ;\n3. Has an implanted IOL in the study eye and a refraction of the study eye outside of -4D; +4D limit (this criterion is not relevant for phakic eyes)\n4. Has a highly myopic study eye (\\>26 mm AP);\n5. Has no light perception in either eye;\n6. Has a history of documented choroidal neovascularization in either eye;\n7. Has any signs of exudative AMD including exudative AMD with detachment of retinal pigment epithelium in the central visual field of the study eye;\n8. Has an implanted telescope in one eye;\n9. Has a black IOL in the study eye;\n10. Has any disease (other than study allowed diseases) or condition that affects retinal function of the study eye or the visual system (e.g., central retinal artery\u002Fvein occlusion, end-stage diabetic retinopathy, Proliferative Diabetic Retinopathy (PDR), diabetic macular oedema (DME), severe Non-Proliferative Diabetic Retinopathy (NPDR), retinal detachment, infectious or inflammatory retinal disease, severe glaucoma, optic neuropathy, etc.) ;\n11. Has any disease or condition that prevents adequate examination (including Optical Coherence Tomography (OCT)) of the study eye including but not limited to media opacities that cannot be resolved prior to implantation. Note, that this criterion is also important for the function of the implant;\n12. Has a corneal endothelial cell count of less than 1000 cells\u002Fmm² in the study eye;\n13. Suffers from nystagmus or other ocular motility disorders;\n14. Has any disease or condition that precludes the understanding or communication of the informed consent, study requirements or test protocols (e.g., deafness, severe multiple sclerosis, amyotrophic lateral sclerosis, severe neuritis, etc.);\n15. Has uncontrolled epileptic seizures;\n16. Has a known sensitivity to the contact materials of the implant (iridium oxide, silicon-carbide and titanium);\n17. Has a known allergy to anaesthetic drugs;\n18. Presents with hypotonia in the study eye (\\\u003C8 mmHg);\n19. Presents with hypertonia in the study eye (\\>23 mmHg with treatment);\n20. Has active cancer or a history of intraocular, optic nerve or brain cancer and metastasis;\n21. Is an immune-suppressed participant (e.g., due to HIV positive diagnosis, etc.);\n22. Is a known carrier of multi-resistant microorganisms;\n23. Is receiving anticoagulation therapy that cannot be adapted to allow eye surgery;\n24. Is participating in another investigational drug or device study that may interfere with the PRIMAlia study;\n25. Has a history of chronic or recurrent infection or inflammation that would preclude participation in the study;\n26. Has significant recurrent or chronic inflammations or infections. Specifically, patients with the following disorders are excluded:\n\n    * Severe chronic and consuming diseases that frequently associated with infection (e.g. Crohn disease, Whipple's disease);\n    * Active inflammation in the area of the eye (e.g. herpes of cornea and\u002For conjunctiva, recurrent blepharoconjunctivitis, hordeolum, chalazion);\n27. Has a severe psychological disorder;\n28. Does not have the mental capacity to legally sign the informed consent;\n29. Has severe renal, cardiac, hepatic, etc. organ diseases (ASA IV or worse);\n30. Has head dimensions that are incompatible with the PRIMA Companion glasses;\n31. Has too high and\u002For unrealistic expectations (e.g., believes that a benefit is guaranteed or expects normal vision after surgery).\n32. Physical constraints making use of PRIMA or rehabilitation impossible\n33. Participant who, in the opinion of the investigator, is not suitable for participation in the study",{"count":272,"type":20},5,[23],"The objective of this study is to evaluate the efficacy and safety of the PRIMA Products in participants with inherited retinal degeneration affecting the macula (including but not limited to Stargardt disease, and Retinitis Pigmentosa).\n\nEligible participants will be implanted with the PRIMA Stim implant. The participants will be assessed with various visual function and functional vision tests at defined timepoints throughout the clinical investigation with the PRIMA Products. The purpose of this study is to gather enough clinical data to support the clinical evaluation required for the continuous development to improve the PRIMA Products.",[276,26,277],"Stargardt Disease","Inherited Retinal Degeneration","2026-03-27",{"date":280,"type":68},"2026-04-02",{"date":282,"type":20},"2026-03-12",{"date":284,"type":20},"2031-03-01",{"name":286,"class":101},"Science Corporation",{"id":288,"slug":289,"hasResults":11,"nctId":290,"briefTitle":291,"officialTitle":292,"acronym":293,"eligibilityCriteria":294,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":295,"enrollmentInfo":296,"targetDuration":4,"studyType":21,"phases":297,"briefSummary":298,"conditions":299,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":300,"lastUpdatePostDateStruct":301,"startDateStruct":303,"completionDateStruct":305,"leadSponsor":307,"locationsCount":75},"100615467","implementation-and-evaluation-of-a-post-diagnostic-announcement-protocol-at-the-crmr-referet-quinze-vingts-hospital-100615467","NCT07292987","Implementation and Evaluation of a Post-Diagnostic Announcement Protocol at the CRMR RefeRet, Quinze-Vingts Hospital","Implementation and Evaluation of a Post-diagnostic Announcement Protocol at the CRMR RefeRet of the Quinze-Vingts National Ophthalmology Hospital","RP-DIAG","Inclusion Criteria:\n\n* Diagnosed with retinitis pigmentosa (RP) and followed at the Quinze-Vingts Rare Eye Disease Center, with diagnosis made after the project begins\n* Aged 18 to 65 years\n* Male or female\n* French-speaking\n* Have a phone number\n* Reside in France\n\nExclusion Criteria:\n\n* Pregnant women\n* Participants enrolled in a therapeutic clinical trial within the past 12 months\n* Individuals deprived of liberty by judicial or administrative decision\n* Adults under legal protection or unable to provide informed consent\n* Individuals with other medical conditions or taking treatments that could interfere with study evaluations","65 Years",{"count":84,"type":20},[23],"This study explores whether adding early nurse-led and psychological support after the diagnosis of retinitis pigmentosa (RP) can improve patient experience and emotional well-being. RP is a rare, progressive eye disease often diagnosed after a long and difficult process, and receiving the diagnosis can be emotionally distressing.\n\nEighty newly diagnosed adults will be randomly assigned to either usual care or an enhanced pathway that includes early follow-up with a nurse, structured emotional monitoring, and a psychologist visit at six months.\n\nThe study aims to determine if this structured support improves patient satisfaction and reduces anxiety and depression compared with standard care.",[26],"2026-02-09",{"date":302,"type":68},"2026-02-10",{"date":304,"type":68},"2025-12-01",{"date":306,"type":20},"2028-01",{"name":308,"class":74},"Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts",{"id":310,"slug":311,"hasResults":11,"nctId":312,"briefTitle":313,"officialTitle":314,"acronym":315,"eligibilityCriteria":316,"healthyVolunteers":317,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":318,"targetDuration":4,"studyType":153,"phases":4,"briefSummary":320,"conditions":321,"keywords":336,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":343,"lastUpdatePostDateStruct":344,"startDateStruct":346,"completionDateStruct":348,"leadSponsor":350,"locationsCount":4},"100615866","wide-field-octa-in-ocular-diseases-100615866","NCT07298174","Wide Field OCTA in Ocular Diseases","Wide Field OCTA in Ocular Diseases: a Prospective Observational Study of the Clinical Impact of Wide Field OCTA in Ocular Disease.","WOOD-2025","Inclusion Criteria:\n\n* Age \\> 18 years\n* Both genders\n* Confirmed diagnosis of one of the above diseases\n* Age-related macular degeneration\n* Diabetic retinopathy\n* Myopia\n* Pachychoroid spectrum disease\n* Inherited retinal dystrophy\n* Uveitis\n* Dry eye\n* Visual acuity of at least 1\u002F20\n* Signed informed consent for the participation to the trial.\n\nExclusion Criteria:\n\n* Media opacities\n* Any other eye or systemic condition that may irreversibly impair the results of the study\n* Surgery in the eye in the study, including cataract extraction, in the three months prior to recruitment",true,{"count":319,"type":20},200,"The main retinal diseases, whether or not associated with specific mutations genetic, cause progressive degeneration of vascular retinal structures and not vascular, resulting in decreased visual function. Often, such diseases affect the noblest part of the retina, called macula. Many retinal diseases can be complicated by choroidal neovascularization which causes frequent bleeding and fluid leakage that accumulates in the subretinal and intraretinal spaces. Although the investigators know many details of each disease affecting the retina, very often the correct diagnostic framework can be complicated, given the presence of morphological elements common to the different pathologies. Similarly, predicting the effect of treatment and the patient's outcome is a constant challenge for the ophthalmologists. Most of the current research has been focused on the assessment of vascular alterations localized in the macula. However, growing evidence highlight the importance of peripheral vascular changes on the outcome of retinal diseases. These changes can be detected only be wide field OCT devices.\n\nOn the other hand, ocular inflammation and hyperemia represent major assessments in anterior segment disorders, such as dry eye disease. The current grading systems of ocular inflammation, redness and hyperemia are characterized by several limitations, thus making these evaluations still mainly confined to the subjective assessment performed by the ophthalmologist. However, the new generation OCT devices may include also an anterior segment module which can reconstruct anterior segment vessels, non-invasively, using the same technology described for retinal diseases.\n\nThe main goal of the study is to evaluate the diagnostic contribution of a new generation wide field OCTA device in ocular diseases, which has recently received CE marking. In particular, the investigators will evaluate this new generation device both in retinal and anterior segments diseases, testing for common points and differences with the standard of care non-invasive diagnostic devices. Secondary outcomes include the assessment of the correlation between the patient's visual function (visual acuity) and morphological changes (standard of care imaging assessment) highlighted by the wide field OCT device, with particular attention to microstructural differences between major ocular diseases and the possible development of non-invasive biomarkers, useful for the diagnosis and follow-up of such pathologies.",[322,323,324,325,326,276,26,327,328,329,330,331,332,333,334,335],"Age - Related Macular Degeneration (AMD)","Diabetic Macular Edema","Diabetic Retinopathy","Myopia","Inherited Retinal Disease","Best Disease","Geographic Atrophy","Macular Neovascularisation","Ocular Surface Disease","Central Serous Choroidopathy","Pachychoroid Disease","Uveitis","Vitreoretinal Disease","Retinal Vein Occlusion",[337,338,339,340,341,342],"wide-field octa","multimodal retinal imaging","quantitative imaging","retinal disease","macular disease","ocular surface disease","2025-12-22",{"date":345,"type":68},"2025-12-30",{"date":347,"type":20},"2026-01",{"date":349,"type":20},"2028-05",{"name":351,"class":74},"IRCCS San Raffaele",{"id":353,"slug":354,"hasResults":11,"nctId":355,"briefTitle":356,"officialTitle":357,"acronym":4,"eligibilityCriteria":358,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":359,"targetDuration":4,"studyType":21,"phases":361,"briefSummary":363,"conditions":364,"keywords":365,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":369,"lastUpdatePostDateStruct":370,"startDateStruct":372,"completionDateStruct":373,"leadSponsor":374,"locationsCount":75},"100616918","early-phase-1-ugx202-injection-in-patients-with-advanced-retinitis-pigmentosa-100616918","NCT07311863","UGX202 Injection in Patients With Advanced Retinitis Pigmentosa","Study to Evaluate the Safety and Preliminary Efficacy of UGX202 Injection in Patients With Advanced Retinitis Pigmentosa","Inclusion Criteria:\n\n* Provide written informed consent form (ICF).\n* Age ≥18 years at ICF signing.\n* Diagnosed as non-syndromic RP；\n* BCVA \\> logMAR 1.9 (assessed by FrACT) in the study eye.\n* Confirmation of preserved memory of visual experience\n* Spherical equivalent between -9D and +6D.\n\nExclusion Criteria:\n\n* Prior gene therapy in either eye.\n* Received any interventional investigational drug within 90 days prior to screening.\n* Any Study eye disease or systemic disease judged by the investigator to affect visual function assessment.\n* Hypersensitivity to corticosteroids, intolerance to corticosteroid regimen, active concurrent infection contraindicating treatment.\n* History or tendency of psychiatric disorders impacting safety and\u002For efficacy assessment.\n* Any other factor deemed unsuitable by the investigator.",{"count":360,"type":20},6,[362],"EARLY_PHASE1","The primary objective of this clinical trial is to evaluate the safety and tolerability of a single intravitreal injection of the gene therapy drug UGX202 in patients with advanced RP. The secondary objective is, to assess the preliminary efficacy of a single intravitreal injection of the gene therapy drug UGX202 in treating patients with advanced RP.",[26],[366,367,368,126,216],"UGX202","UGENEXIIT002","retinitis pigmentosa","2025-12-16",{"date":371,"type":68},"2025-12-31",{"date":347,"type":20},{"date":173,"type":20},{"name":375,"class":74},"Suzhou UgeneX Therapeutics Co., Ltd.",{"id":377,"slug":378,"hasResults":11,"nctId":379,"briefTitle":380,"officialTitle":381,"acronym":382,"eligibilityCriteria":383,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":384,"targetDuration":4,"studyType":153,"phases":4,"briefSummary":385,"conditions":386,"keywords":4,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":388,"lastUpdatePostDateStruct":389,"startDateStruct":391,"completionDateStruct":393,"leadSponsor":395,"locationsCount":75},"100613385","inherited-retinal-diseases-natural-history-and-genotype-phenotype-correlations-100613385","NCT07265895","Inherited Retinal Diseases: Natural History and Genotype-Phenotype Correlations","Inherited Retinal Diseases: Natural History and Genotype-Phenotype Correlations, Monocentric Retrospective Observational Study","IRDs-OSR","Inclusion Criteria:\n\n1. Participant completed at least one ophthalmological and retinal imaging examination at our center.\n2. Clinically diagnosed with IRD, as per familiy history, clinical signs or symptoms, retinal imaging findings.\n3. Definitive genetic diagnosis of IRD with adequate molecular test\n\nExclusion Criteria:\n\n1. Affected by other retinal or optic nerve conditions potentially affecting analyses (diabetic retinopathy, glaucoma).\n2. History of retinotoxic medications (i.e., hydroxychloroquine, pentosan polysulfate sodium, tamoxifen, ritonavir, didanosine, MEK inhibitors) intake.\n3. Unclear genetic diagnosis.\n4. Incomplete or inadequate ophthalmological and imaging tests.",{"count":319,"type":20},"Inherited Retinal Diseases (IRDs) are a heterogeneous group of genetically based degenerative retinal disorders, representing a major cause of visual impairment and blindness in working-age adults. Despite the approval of the first gene therapy for RPE65-related IRD (voretigene neparvovec) in 2017, most IRDs remain untreatable, though many gene therapies are in development. Effective trial design and therapy development require a deep understanding of disease natural history and genotype-phenotype correlations. Over 270 IRD-associated genes are known (e.g., ABCA4, USH2A, RPGR, PRPH2, BEST1), each linked to distinct phenotypes and clinical progression. This retrospective study analyzes clinical, functional, and imaging data (Optical Coherence Tomography, Fundus Autofluorescence, Microperimetry) from a large, genetically characterized IRD cohort at the IRCCS Ospedale San Raffaele up to December 31, 2025. The aims are to describe natural history, define genotype-phenotype relationships, and identify structural and functional outcome measures useful for future clinical trial endpoints, supporting personalized prognosis and trial design.",[387,26,276],"Retinal Degenerations","2025-12-04",{"date":390,"type":68},"2025-12-05",{"date":392,"type":20},"2026-01-01",{"date":394,"type":20},"2028-12-31",{"name":351,"class":74},{"id":397,"slug":398,"hasResults":11,"nctId":399,"briefTitle":400,"officialTitle":401,"acronym":402,"eligibilityCriteria":403,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":404,"targetDuration":4,"studyType":21,"phases":406,"briefSummary":407,"conditions":408,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":410,"lastUpdatePostDateStruct":411,"startDateStruct":413,"completionDateStruct":415,"leadSponsor":417,"locationsCount":419},"100576606","phase-1-evaluating-a-new-peptide-therapy-for-retinal-diseases-amd-diabetic-retinopathy-and-dystrophies-100576606","NCT06787482","Evaluating a New Peptide Therapy for Retinal Diseases: AMD, Diabetic Retinopathy, and Dystrophies","Open Label, Interventional Single Arm Study Evaluating a New Peptide Therapy for Retinal Diseases: AMD, Diabetic Retinopathy, and Dystrophies","Retino","Inclusion Criteria:\n\n* • Adults aged 18-65 years with a confirmed genetic or clinical diagnosis of RP.\n\n  * Visual acuity of ≥1\u002F60 in at least one eye.\n  * Stable ocular and systemic condition over the past six months.\n  * Ability to provide written informed consent\n\nExclusion Criteria:\n\n* • Significant ocular comorbidities (e.g., advanced glaucoma, diabetic retinopathy).\n\n  * Recent ocular surgery (within six months) or current use of investigational drugs.\n  * Systemic conditions affecting study outcomes (e.g., uncontrolled diabetes, autoimmune diseases).\n  * Pregnancy or lactation.",{"count":405,"type":20},100,[211,114],"Summary of the Study This clinical trial evaluates a novel peptide-based therapy for treating retinal dystrophies, age-related macular degeneration (AMD), and diabetic retinopathy (DR). The therapy consists of peptides derived from fetal tissues, mesenchymal stem cells (MSCs), and bioactive growth factors, administered sublingually for systemic absorption.\n\nStudy Objectives:\n\nPrimary Objectives: Assess safety and tolerability, and evaluate the therapy's effects on retinal function and structure.\n\nSecondary Objectives: Explore improvements in visual acuity, retinal thickness, vascular health, and disease biomarkers.\n\nStudy Design:\n\nType: Open-label, single-arm interventional study. Duration: 12 months.\n\nParticipants: 150 adults, divided into three cohorts:\n\nRetinal dystrophies. AMD (dry and wet forms). DR (moderate NPDR and PDR).\n\nIntervention:\n\nA sublingual solution containing peptides and growth factors, taken 4 times daily.\n\nOutcome Measures:\n\nPrimary Outcomes: Safety (adverse events) and tolerability (treatment adherence).\n\nSecondary Outcomes:\n\nFunctional: Visual acuity and field sensitivity improvements. Structural: Retinal thickness and vascular health. Biomarkers: Serum VEGF, oxidative stress, and inflammatory markers.\n\nStudy Procedures:\n\nMonthly follow-ups for safety monitoring, vision tests, retinal imaging (OCT, FA), and blood biomarker analysis.\n\nComprehensive evaluations at baseline, 6 months, and 12 months. Significance: The study aims to provide an innovative, non-invasive treatment for debilitating retinal conditions, potentially improving vision and retinal health through systemic therapy.",[26,409,324],"Age Related Macular Degeneration","2025-04-23",{"date":412,"type":68},"2025-04-25",{"date":414,"type":68},"2024-11-12",{"date":416,"type":20},"2025-12",{"name":418,"class":101},"Ace Cells Lab Limited",2,{"id":421,"slug":422,"hasResults":11,"nctId":423,"briefTitle":424,"officialTitle":425,"acronym":4,"eligibilityCriteria":426,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":427,"targetDuration":4,"studyType":153,"phases":4,"briefSummary":429,"conditions":430,"keywords":4,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":434,"lastUpdatePostDateStruct":435,"startDateStruct":437,"completionDateStruct":439,"leadSponsor":441,"locationsCount":75},"100585883","functional-assessments-in-vision-impairment-100585883","NCT06908161","Functional Assessments in Vision Impairment","A Novel Approach for Capturing Real-world Functional Assessment Outcomes in Participants With a Vision Impairment","Inclusion Criteria:\n\n1. Willing to provide signed informed consent.\n2. Be available for study visits.\n3. Willing to comply with study assessments.\n4. In good general health and ambulant.\n5. Aged over 18 years of age.\n6. Have a vision impairment caused by any ocular condition which affects independent mobility.\n7. Agree to allow the research team into their home and local environments.\n8. Participate in assessments in public settings\n\nExclusion Criteria:\n\n1. Significant co-morbidities which prohibit involvement in study visits.\n2. Anything that would place the individual at increased risk or preclude the individual's full compliance with or completion of the study.\n3. Cognitive deficiencies, including dementia or progressive neurological disease.\n4. Have a psychiatric condition that, in the investigator's opinion, precludes compliance with the protocol including past or present psychoses and bipolar disorder.\n5. Deafness or significant hearing loss.\n6. Inability to converse in English.",{"count":428,"type":20},45,"The aim of the research project is to validate the use of a novel functional assessment tool designed to document how participants with a vision impairment complete activities of daily living in a real world environment.",[26,431,432,36,433],"Diabetic Retinopathy (DR)","Age Related Macular Degeneration (AMD)","Retinal Dystrophy","2025-03-26",{"date":436,"type":68},"2025-04-03",{"date":438,"type":20},"2025-04-01",{"date":440,"type":20},"2027-12-31",{"name":442,"class":74},"Center for Eye Research Australia",{"id":444,"slug":445,"hasResults":11,"nctId":446,"briefTitle":447,"officialTitle":448,"acronym":4,"eligibilityCriteria":449,"healthyVolunteers":317,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":450,"targetDuration":4,"studyType":21,"phases":452,"briefSummary":453,"conditions":454,"keywords":4,"overallStatus":92,"whyStopped":4,"lastUpdateSubmitDate":457,"lastUpdatePostDateStruct":458,"startDateStruct":460,"completionDateStruct":462,"leadSponsor":463,"locationsCount":4},"100581118","retinal-investigation-using-optos-oct-device-100581118","NCT06846151","Retinal Investigation Using Optos OCT Device","Clinical Investigation of Optos OCT in Patients with Retinal Pathologies","Inclusion Criteria:\n\n1. Male or female participants 18 years of age or older who have full legal capacity to volunteer on the date the informed consent is signed.\n2. Participants who understand the study and patient information sheet and can follow the instructions.\n3. Participants who agree to participate in the study.\n4. Control group where no retinal abnormalities were detected as part of the standard basic ophthalmic examination.\n5. Participants with retinal disease in at least one eye including: Early dry age-related macular degeneration, late stage dry age-related macular degeneration specifically geographic atrophy, Wet age-related macular degeneration, Retinitis pigmentosa, Diabetic retinopathy and other macular atrophic diseases\n\nExclusion Criteria:\n\n1. Inability to understand written and verbal English sufficiently to comprehend the study and provide informed consent\n2. Ophthalmic disease other than condition under investigation.\n3. Participants unable to tolerate ophthalmic imaging.\n4. Cataract (unless deemed mild in the opinion of the investigator)\n5. Participants with significant ocular media not sufficiently clear to obtain acceptable OCT images.\n6. Diabetes (unless part of the diabetic eye disease group)\n7. Binocular visual acuity worse than 6\u002F18\n8. Strabismus (squint)\n9. Age related macular degeneration groups: polypoidal choroidal vasculopathy\n10. Participants with photo sensitivity epilepsy, experience of seizures, or sensitivity to flickering light (based on self-report)\n11. Pregnant",{"count":451,"type":20},120,[23],"Retinal investigation using OCT with control and diseased eyes",[455,26,324,456],"AMD - Age-Related Macular Degeneration","Control Patients","2025-02-20",{"date":459,"type":68},"2025-02-25",{"date":461,"type":20},"2025-05",{"date":347,"type":20},{"name":464,"class":101},"Optos, PLC"]